GlassScriptPhysician profile
Jillian Rose Greer
NPI 1063042513
$18,447.96
in general payments reported to CMS, 2019-2025
47 companies · $3,620 in 2025
The $3,620 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,664 · 2022: $4,106 · 2023: $4,172 · 2024: $3,886 · 2025: $3,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $708 · Education: $46.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,923.53 |
| Travel and Lodging | $707.77 |
| Education | $46.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $2,746.53 | 2021-2025 | Isturisa, Signifor Lar |
| Lilly USA, LLC | $2,225.67 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,708.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $1,525.33 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbvie INC. | $1,156.00 | 2021-2025 | |
| Corcept Therapeutics | $1,153.22 | 2021-2025 | Korlym |
| Mannkind Corporation | $973.93 | 2021-2025 | Afrezza |
| Amgen INC. | $651.99 | 2021-2025 | Tepezza, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.05 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Eusa Pharma (US) LLC | $488.55 | 2022 | |
| Ascensia Diabetes Care US INC. | $483.86 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $466.52 | 2021-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $386.46 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $333.23 | 2021-2023 | |
| Cequr Corporation | $316.71 | 2022-2024 | Cequr Simplicity |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $298.06 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $288.76 | 2022-2025 | |
| Madrigal Pharmaceuticals | $280.28 | 2025 | Rezdiffra |
| Dexcom, INC. | $249.47 | 2021-2024 | Dexcom G6 Transmitter |
| Intuity Medical INC | $246.01 | 2022 | |
| Insulet Corporation | $240.24 | 2021-2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $171.29 | 2021-2025 | |
| Esperion Therapeutics, INC. | $169.52 | 2021-2023 | Nexletol |
| Beta Bionics, INC. | $137.28 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $136.20 | 2021-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $133.23 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $124.02 | 2023-2025 | Contrave, Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.76 | 2022-2024 | Cycloset |
| Antares Pharma, INC. | $102.09 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $55.51 | 2023-2024 | Veozah |
| Amryt Pharma Holdings LTD | $52.84 | 2022 | |
| Avvisto Therapeutics, LLC | $46.31 | 2024-2025 | Cycloset |
| Zealand Pharma US, INC. | $45.07 | 2021-2022 | |
| Pfizer INC. | $39.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $33.06 | 2023 | Linzess |
| Halozyme INC | $32.49 | 2023 | |
| Sequel Med Tech, LLC | $29.90 | 2025 | Twiist |
| Embecta Corp. | $27.72 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Itamar Medical INC | $25.95 | 2023 | Watchpatone |
| Ultragenyx Pharmaceutical INC. | $25.95 | 2022 | |
| Tandem Diabetes Care, INC. | $24.07 | 2021-2022 | |
| Radius Health, INC. | $22.61 | 2024 | Tymlos |
| Ascendis Pharma Endocrinology INC | $21.56 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $20.63 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.25 | 2023 | Adthyza |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Arexvy |
| Clarus Therapeutics INC. | $7.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.